Kyverna Therapeutics Inc. (KYTX)
NASDAQ: KYTX
· Real-Time Price · USD
3.21
0.27 (9.18%)
At close: Jun 06, 2025, 12:55 PM
9.18% (1D)
| Bid | 3.21 |
| Market Cap | 138.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -145.42M |
| EPS (ttm) | -3.36 |
| PE Ratio (ttm) | -0.96 |
| Forward PE | -0.91 |
| Analyst | Buy |
| Ask | 3.22 |
| Volume | 245,192 |
| Avg. Volume (20D) | 316,722 |
| Open | 3.07 |
| Previous Close | 2.94 |
| Day's Range | 3.07 - 3.31 |
| 52-Week Range | 1.78 - 16.64 |
| Beta | 2.54 |
About KYTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KYTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KYTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+13.66%
Kyverna Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
10 months ago
+1.23%
Kyverna Therapeutics shares are trading higher after the company announced it received FDA Regenerative Medicine Advanced Therapy designation for KYV-101 in the treatment of patients with refractory stiff-person syndrome.
